The European Cancer Congress 2015

login
My congress planner
close
Forgot password

Create account

Searchable Programme for ECC2015

Keyword / Author:
  • 26
    SAT
    10:30 – 12:00
    Immunotherapy in Cancer

    Scientific Symposium: Cellular Immunotherapy of Cancer

    Chair: I. Melero (Spain)

    Co-Chair: C. Figdor (Netherlands)

    10:30
    Optimizing adoptive T-cell therapy
    Speaker: P. Hwu (USA)
    Display Presentation Details

    10:50
    Deploying gene-engineered T–cells in the cancer battlefield
    Speaker: C. June (USA)
    Display Presentation Details

    11:10
    Making the most of dendritic cell-based immunotherapy
    Speaker: C. Figdor (Netherlands)
    Display Presentation Details

    11:30
    Is cancer immunosurveillance relevant?
    Speaker: J. Galon (France)

    Discussion & Roundup

  • 26
    SAT
    15:15 – 16:15
    Immunotherapy in Cancer

    Special Session: Combining Radiation and Immunotherapy

    Chair: A. Melcher (United Kingdom)

    15:15
    Molecular basis for radiotherapy in synergy with immunotherapy
    Speaker: S. Demaria (USA)
    Display Presentation Details

    15:25
    Radiotherapy, immunotherapy and virotherapy riddles
    Speaker: K. Harrington (United Kingdom)

    15:35
    Learning radioimmunotherapy
    Speaker: P. Beckhove (Germany)
    Display Presentation Details

    Discussion

  • 27
    SUN
    09:15 – 10:25
    Abstract nr
    Immunotherapy in Cancer

    Proffered Paper Session: Immunotherapy in Cancer I

    Chair: I. Melero (Spain)

    09:15
    14LBA
    LATE BREAKING ABSTRACT:Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
    Speaker: J. Vansteenkiste (Belgium)
    Display abstract

    09:25
    15LBA
    LATE BREAKING ABSTRACT: High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients
    Speaker: B. Higgs (USA)
    Display abstract

    09:35
    16LBA
    LATE BREAKING ABSTRACT: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
    Speaker: B. Besse (France)
    Display abstract

    09:45
    Discussant : L. Paz-Ares (Spain)

    09:55
    17LBA
    LATE BREAKING ABSTRACT: Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC
    Speaker: B. Rini (USA)
    Display abstract

    10:05
    18LBA
    LATE BREAKING ABSTRACT: PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer
    Speaker: J. Yearley (USA)
    Display abstract

    10:15
    Discussant : I. Melero (Spain)

  • 27
    SUN
    09:15 – 11:15
    Immunotherapy in Cancer

    Educational Symposium: Advances in Cancer Therapy Through Modulation of the Immune System

    Chair: B. Van den Eynde (Belgium)

    09:15
    Role of the immune system on the outcome of cancer therapy
    Speaker: A. Marabelle (France)

    09:40
    How does ionising radiation contribute to the induction of anti-tumour immunity?
    Speaker: G. Multhoff (Germany)
    Display Presentation Details

    10:05
    Targeting tumour microenvironment
    Speaker: P. Allavena (Italy)
    Display Presentation Details

    10:30
    Adoptive cell therapy
    Speaker: R. Hawkins (United Kingdom)
    Display Presentation Details

    Discussion & Roundup

  • 27
    SUN
    17:05 – 18:55
    Abstract nr
    Immunotherapy in Cancer

    Proffered Paper Session: Immunotherapy in Cancer II

    Chair: I. Melero (Spain)

    Chair: A. Marabelle (France)

    17:05
    500
    Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028
    Speaker: P. Ott (USA)
    Display abstract

    17:20
    501
    Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial
    Speaker: S. George (USA)
    Display abstract

    17:35
    502
    Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028
    Speaker: B. O’Neil (USA)
    Display abstract

    17:50
    503
    Pneumonitis with anti-PD-1/PD-L1 therapy
    Speaker: J. Naidoo (USA)
    Display abstract

    18:05
    Discussant : K. Harrington (United Kingdom)

    18:15
    504
    Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study
    Speaker: S. Bhatia (USA)
    Display abstract

    18:30
    505
    Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine
    Speaker: J. Tabernero (Spain)
    Display abstract

    18:45
    Discussant : S. Demaria (USA)

Print all results list